Cardiovascular Pathology
Volume 19, Issue 2 , Pages 94-101 , March 2010

The Ras antagonist farnesylthiosalicylic acid ameliorates experimental myocarditis in the rat

  • Rakefet Pando

      Affiliations

    • Department of Cardiology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
    • Department of Neurobiochemistry, George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel
    • ,
  • Iris Barshack

      Affiliations

    • Institute of Pathology, Sheba Medical Center, Tel Hashomer, Israel
    • ,
  • Alon Raz

      Affiliations

    • Department of Cardiology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
    • ,
  • Galia Luboshits

      Affiliations

    • Department of Cardiology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
    • ,
  • Ronit Haklai

      Affiliations

    • Department of Neurobiochemistry, George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel
    • ,
  • Sofia Maysel-Auslender

      Affiliations

    • Department of Cardiology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
    • ,
  • Yoel Kloog

      Affiliations

    • Department of Neurobiochemistry, George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel
    • ,
  • Gad Keren

      Affiliations

    • Department of Cardiology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
    • ,
  • Jacob George

      Affiliations

    • Department of Cardiology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
    • Corresponding Author InformationCorresponding author. Fax: +972 3 5469832.

Received 16 September 2007 ,Revised 7 August 2008 ,Accepted 21 October 2008.

References 

  1. Smith SC, Allen PM. Myosin-induced acute myocarditis is a T-cell-mediated disease. J Immunol. 1991;147:2141–2147
  2. Cunningham MW. Cardiac myosin and the TH1/TH2 paradigm in autoimmune myocarditis. Am J Pathol. 2001;159:5–9
  3. Lieberman EB, Hutchins GM, Herskowitz A, et al. Clinicopathologic description of myocarditis. J Am Coll Cardiol. 1991;18:1617–1626
  4. Huber SA, Job LP, Woodruff JF. Lysis of infected myofibers by coxsackievirus B3 immune T lymphocytes. Am J Pathol. 1980;98:681–694
  5. Alvarez FL, Neu N, Rose NR, et al. Heart-specific autoantibodies induced by coxsackievirus B3: identification of heart autoantigens. Clin Immunol Immunopathol. 1987;43:129–139
  6. Nue N, Rose NR, Beisel KW, et al. Cardiac myosin induces myocarditis in genetically predisposed mice. J Immunol. 1987;139:3630–3636
  7. Kodama M, Matsumoto Y, Fujiwara M, et al. A novel experimental model of giant cell myocarditis induced in rats by immunization with cardiac myosin fraction. Clin Immunol Immunopathol. 1990;57:250–262
  8. Kodama M, Izumi T. Experimental autoimmune myocarditis. Acta Med Biol. 1991;39:1–10
  9. Kodama M, Matsumoto Y, Fujiwara M, et al. Characteristics of giant cells and factors related to the formation of giant cells in myocarditis. Circ Res. 1991;69:1042–1050
  10. Kodama M, Matsumoto Y, Fujiwara M. In vivo lymphocyte-mediated myocardial injuries demonstrated by adoptive transfer of experimental autoimmune myocarditis. Circulation. 1992;85:1918–1926
  11. Okura Y, Takeda M, Honda S, et al. Recombinant murine interleukin-12 facilitates induction of cardiac myosin-specific type 1 helper T cells in rats. Circ Res. 1998;82:1035–1042
  12. Kodama M, Hanawa H, Saeki M, et al. Rat dilated cardiomyopathy after autoimmune giant cell myocarditis. Circ Res. 1994;75:278–284
  13. Downward J. Ras signaling and apoptosis. Curr Opin Gen Dev. 1998;8:49
  14. Katzav A, Kloog Y, Korczyn D, et al. Treatment of MRL/lpr mice, a genetic autoimmune model, with the Ras inhibitor, FTS. Clin Exp Immunol. 2001;126:570–577
  15. Jansen B, Schlagbauer-Wadl H, et al. Novel Ras antagonist blocks human melanoma growth. Proc Natl Acad Sci U.S.A. 1999;96:14019–14024
  16. Kafri M, Kloog Y, Korczyn AD, et al. Inhibition of Ras attenuates the course of experimental autoimmune neuritis. J Neuroimmunol. 2005;168(1–2):46–55
  17. Marciano D, Ben-Baruch G, Marom M, et al. Farnesyl derivatives of rigid carboxylic acids — inhibitors of Ras-dependent cell growth. J Med Chem. 1995;38:1267–1272
  18. George J, Biner S, Keren P, Barshack I, Goldberg I, Sherez J, et al. Tyrphostin AG-556 reduces myocardial infarct size and improves cardiac performance in the rat. Exp Mol Pathol. 2003;74(3):314–318
  19. Haklai R, Weisz MG, Elad G, et al. Dislodgment and accelerated degradation of Ras. Biochemistry. 1998;37:1306–1314
  20. George J, Adler A, Barshack I, et al. Suppression of myosin-induced and adoptively transferred myocarditis by prior treatment with complete Freund's adjuvant. Cardiovasc Pathol. 2004;13:221–224
  21. Godsl LM, Wang K, et al. Prevention of autoimmune myocarditis through the induction of antigen-specific peripheral immune tolerance. Circulation. 2001;103:1709–1714
  22. June CH. Signal transduction in T cells. Curr Opin Immunol. 1991;3:287–293
  23. Karusis D, Abramsky O, Grigoriadis N, Chapman J, Mizrachi-Koll R, Niv H, et al. The Ras-pathway inhibitor, S-trans-trans-farnesylthiosalicylic acid (FTS), suppresses experimental allergic encephalomyelitis. J Neuroimmunol. 2001;120(1–2):1–9
  24. Katzav A, Kloog Y, et al. Treatment of MRL/lpr mice, a genetic autoimmune model, with the Ras inhibitor, farnesylthiosalicylate (FTS). Clin Exp Immunol. 2001;126:570–577
  25. George J, Sack J, Barashack I, Keren P, Goldberg I, Haklai R, et al. Inhibition of intimal thickening in the rat carotid artery injury model by non-toxic Ras inhibitor. Arterioscler Thromb Vasc Biol. 2004;24:363–368150
  26. George J, Afek A, Keren P, Goldberg I, Shapiro R, Haklai R, et al. Functional inhibition of Ras by farnesylthiosalicylic acid (FTS) attenuates atherosclerosis in apolipoprotein E knockout mice. Circulation. 2002;105:2416–2422
  27. Afanasyeva M, Georgakopoulos D, et al. Autoimmune myocarditis: cellular mediators of cardiac dysfunction. Elsevier Autoimmun Rev. 2004;3:476–486
  28. Katzav A, Kloog Y, et al. Inhibition of Ras by farnesylthiosalicylate significantly reduces the levels of autoantibodies in two animal models of the antiphospholipid syndrome. Immunobiology. 2003;207(1):47–50

 This study was supported in part by a grant from the Israeli Science Foundation (J.G., no. 832/06).

PII: S1054-8807(08)00154-3

doi: 10.1016/j.carpath.2008.10.009

Cardiovascular Pathology
Volume 19, Issue 2 , Pages 94-101 , March 2010

Article Tools

* Image Usage & Resolution